Supplementary Materials

The PDF file includes:

  • Fig. S1 (related to Fig. 1). Intracellular antibody expression in circulating plasmablasts.
  • Fig. S2 (related to Fig. 1). Circulating TFH cells in blood of SARS-CoV-2-infected patients.
  • Fig. S3 (related to Fig. 2). Reproducibility of photonic ring immunoassay to detect anti-RBD and anti-NC antibodies.
  • Fig. S4 (related to Fig. 2). Early detection of anti-RBD antibodies in serum from SARS-CoV-2-infected patients.
  • Fig. S5 (related to Fig. 3). Neutralizing activity of serum, BAL, and saliva from SARS-CoV-2-infected patients.
  • Table S1. Demographics, baseline characteristics, treatment, and outcome of 38 COVID-19 patients assessed for blood plasmablasts.
  • Table S2. Demographics and baseline characteristics of COVID-19 patients.
  • Table S3. Clinical characteristics, laboratory results, treatment, and outcome of COVID-19 patients.
  • Table S4. Virus-specific IgG, IgM, and IgA titers according to the clinical course of the disease in COVID-19 patients.
  • Table S5. Demographics, baseline characteristics, treatment, and outcome of patients with acute respiratory distress syndrome during the course of COVID-19.
  • Table S6. Human antibodies used for B and T cell phenotyping.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Raw data spreadsheet.